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ABSTRACT 
Different mass transport processes may occur during drug release from polymer-based matrix tablets, including water imbibition into the 
system, polymer swelling, drug dissolution, drug diffusion out of the tablet, and polymer dissolution. Depending on the type of drug, polymer 
and release medium and on the tablet composition, the respective processes are more or less important. Velasco et al.24 reported that the rate 
and mechanism of nifidipine release from HPMC K15M-based matrices were mainly controlled by the drug/ HPMC ratio, and that drug release 
was independent of the compression force in the range between 3 and 12 kN. The effects of the two formulation variables ‘‘HPMC/ lactose 
ratio’’ and ‘‘HPMC viscosity grade’’ on the release of adinazolam mesylate from cylindrical tablets was studied by Sung et al . The resulting drug 
release rate was found to increase with decreasing ‘‘HPMC/ lactose ratio’’ and decreasing ‘‘HPMC viscosity grade 
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Different studies reported in the literature indicate that 
pharmaceutical dosage forms exhibiting good in vitro 
floating behavior show prolonged gastric residence in vivo 
1,2,3,4. The physical properties of the drug delivery system 
(e.g., density and size) as well as the presence of food in the 
stomach have been identified as the two most important 
parameters determining the in vivo performance of the 
dosage form5. Under fasted conditions the stomach is cleared 
of undigested material every 1.5 to 2 h by housekeeper 
waves. To provide good floating behavior in the stomach, the 
density the density of the device should be less than that of 
the gastric contents (1.004 g/cm3). However, it has to be 
pointed out that good in vitro floating behavior alone is not 
sufficient proof for efficient gastric retention in vivo. The 
effects of the simultaneous presence of food and of the 
complex motility of the stomach are difficult to estimate. 
Obviously, only in vivo studies can provide definite proof 
that prolonged gastric residence is obtained. 
2. BASIC PHYSIOLOGY OF THE GASTROINTESTINAL 
TRACT: 
Anatomically the stomach is divided into three regions: 
fundus, body, and antrum (pylorus). The proximal part made 
of fundus and body acts as a reservoir for undigested 
material, whereas the antrum is the main site for mixing 
motions and act as a pump for gastric emptying by propelling 
actions.12 
Gastric emptying occurs during fasting as well as fed states. 
The pattern of motility is however distinct in the two states. 
During the fasting state an interdigestive series of electrical 
events take place, which cycle both through stomach and 
intestine every 2 to 3 hours.13 This is called the interdigestive 
myloelectric cycle or migrating myloelectric cycle (MMC), 
which is further divided into following 4 phases as described 
by Wilson and Washington.13 
2.1 Gastric emptying and problems  
It is well recognized that the stomach may be used as a depot 
for Sustained release dosage forms, both in human and 
veterinary applications, stomach is anatomically divided in 
to three parts: Fundus, body and pylorus.15 
The proximal stomach made up of the fundus and body 
region serves as a reservoir for ingested materials, while the 
distal region (antrum) is the major site for the mixing 
motion, acting as a pump to accomplish gastric emptying. 
The process of the gastric emptying occurs both during 
fasting and fed stages. 
2.2 Approaches to gastric retention  
Various approaches have been paused to increase the 
duration of oral dosage form in the stomach, including 
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floating systems, swelling and expanding system, modified 
shape system, high density systems and other delayed gastric 
emptying devices. (Magnetic systems, Super porous –
biodegradable hydrogel systems). 
Hydrodynamically balanced systems (HBS) –incorporated 
buoyant materials enable the device to float.33, 34 
 
Table 1.1 Drawbacks associated with different types of GRDDS 9 
Formulations Drawback 
Incorporation of passage delaying food excipient 
such as fatty acids 
-  Affect the emptying mechanism of the entire content. 
Bio adhesive drug delivery systems -  Adhesive is non specific 
-  Efficiency is limited by the possible interaction with food. 
Biodegradable and non biodegradable (swelling) 
formulation in which the size and shape retain in 
the dosage form. 
- Present the hazard of permanent retention and might lead 
to serious life threatening effects if multiple dosing. 
 
3. APPROACHES TO DESIGN FLOATING DOSAGE 
FORMS: 
The following approaches have been used for the design of 
floating dosage forms of single- and multiple-unit systems.18 
3.1 Single-Unit Dosage Forms 
In Low-density approach21 the globular shells apparently 
having lower density than that of gastric fluid can be used as 
a carrier for drug for its controlled release. A buoyant dosage 
form can also be obtained by using a fluid-filled system that 
floats in the stomach. In coated shells23 popcorn, poprice, and 
polystyrol have been exploited as drug carriers. Sugar 
polymeric materials such as methacrylic polymer and 
cellulose acetate phthalate have been used to undercoat 
these shells. 
4. CLASSIFICATION OF FLOATING DRUG DELIVERY 
SYSTEMS (FDDS) 
Floating drug delivery systems are classified depending on 
the use of two formulation variables: effervescent and non-
effervescent systems. 
4.1 Effervescent Floating Dosage Forms 
These are matrix types of systems prepared with the help of 
swellable polymers such as methylcellulose and chitosan and 
various effervescent compounds, eg, sodium bicarbonate, 
tartaric acid, and citric acid. They are formulated in such a 
way that when in contact with the acidic gastric contents, 
CO2 is liberated and gets entrapped in swollen hydrocolloids, 
which provides buoyancy to the dosage forms. 
 
 
Figure 1.1.  (A) Multiple-unit oral floating drug delivery system. (B) Working principle of effervescent floating drug delivery system. 
 
Yang et al19 developed a swellable asymmetric triple-layer 
tablet with floating ability to prolong the gastric residence 
time of triple drug regimen (tetracycline, metronidazole, and 
clarithromycin) in Helicobacter pylori–associated peptic 
ulcers using HPMC and poly (ethylene oxide) (PEO) as the 
rate-controlling polymeric membrane excipients. The design 
of the delivery system was based on the swellable 
asymmetric triple-layer tablet approach. Tetracycline and 
metronidazole were incorporated into the core layer of the 
triple-layer matrix for controlled delivery, while bismuth salt 
was included in one of the outer layers for instant release. 
The floatation was accomplished by incorporating a gas-
generating layer consisting of sodium bicarbonate: calcium 
carbonate (1:2 ratios) along with the polymers. The in vitro 
results revealed that the sustained delivery of tetracycline 
and metronidazole over 6 to 8 hours could be achieved while 
the tablet remained afloat. (Figure 1.2). 
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Figure 1.2.  Schematic presentation of working of a triple-layer system. (A) Initial configuration of triple-layer tablet. (B) On 
contact with the dissolution medium the bismuth layer rapidly dissolves and matrix starts swelling. (C) Tablet swells and erodes. 
(D) and (E) Tablet erodes completely. 
 
Li et al25 evaluated the contribution of formulation variables 
on the floating properties of a gastro floating drug delivery 
system using a continuous floating monitoring device and 
statistical experimental design. The formulation was 
conceived using taguchi design. HPMC was used as a low-
density polymer and citric acid was incorporated for gas 
generation. Analysis of variance (ANOVA) test on the results 
from these experimental designs demonstrated that the 
hydrophobic agent magnesium stearate could significantly 
improve the floating capacity of the delivery system. 
4.2 Non-Effervescent Floating Dosage Forms 
Non-effervescent floating dosage forms use a gel forming or 
swellable cellulose type of hydrocolloids, polysaccharides, 
and matrix-forming polymers like polycarbonate, 
polyacrylate, polymethacrylate, and polystyrene. The 
formulation method includes a simple approach of 
thoroughly mixing the drug and the gel-forming 
hydrocolloid. After oral administration this dosage form 
swells in contact with gastric fluids and attains a bulk density 
of < 1. 
5. FACTORS AFFECTING GASTRIC RETENTION   
5.1 Density 
The density of a dosage form also affects the gastric 
emptying rate. A buoyant dosage form having a density of 
less than that of the gastric fluids ( 1.004 gm/ml) floats. 
Since it is away from the pyloric sphincter, the dosage unit is 
retained in the stomach for a prolonged period. 
5.2 Size and shape 
To pass through the pyloric valve into the small intestine the 
particle size should be in the range of 1 to 2 mm.26 Dosage 
form unit with a diameter of more than 7.5 mm are reported 
to have an increased GRT compared to those with a diameter 
of 9.9 mm. The dosage form with a shape tetrahedron and 
ring shape devices with a flexural modulus of 48 and 22.5 
kilopond per square inch (KSI) are reported to have better 
GIT ( 90 to 100 %) retention at 24 hours compared with 
other shapes.27,28,29 
5.3 Fasting or fed state 
Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric 
complexes (MMC) that occurs every 1.5 to 2 hours. The MMC 
sweeps undigested material from the stomach and if the 
timing of administration of the formulation coincides with 
that of the MMC, the GRT of the unit can be expected to be 
very short. However, in the fed state, MMC is delayed and 
GRT is considerably longer.36  The pH of the stomach in 
fasting state is ~1.5 to 2.0 and in fed state is 2.0 to 6.0. A 
large volume of water administered with an oral dosage form 
raises the pH of stomach contents to 6.0 to 9.0. Stomach 
doesn’t get time to produce sufficient acid when the liquid 
empties the stomach; hence generally basic drugs have a 
better chance of dissolving in fed state than in a fasting state. 
Studies have revealed that gastric emptying of a dosage form 
in the fed state can also be influenced by its size. Small-size 
tablets leave the stomach during the digestive phase while 
the large-size tablets are emptied during the housekeeping 
waves. 
5.4 Nature of the meal 
The rate of gastric emptying depends mainly on viscosity, 
volume, and caloric content of meals. Nutritive density of 
meals helps determine gastric emptying time. It does not 
make any difference whether the meal has high protein, fat, 
or carbohydrate content as long as the caloric content is the 
same. However, increase in acidity and caloric value slows 
down gastric emptying time.35 Feeding of indigestible 
polymers of fatty acid salts can change the motility pattern of 
the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging the drug release.35 
5.5 Effect of liquid, digestible solid and indigestible solid 
type food 
It has been demonstrated using radiolabeled technique that 
there is a difference between gastric emptying times of a 
liquid, digestible solid, and indigestible solid. It was 
suggested that the emptying of large (>1 mm) indigestible 
objects from stomach was dependent upon interdigestive 
migrating myoelectric complex. When liquid and digestible 
solids are present in the stomach, it contracts ~3 to 4 times 
per minute leading to the movement of the contents through 
partially opened pylorus. Indigestible solids larger than the 
pyloric opening are propelled back and several phases of 
myoelectric activity take place when the pyloric opening 
increases in size during the housekeeping wave and allows 
the sweeping of the indigestible solids. Studies have shown 
that the gastric residence time (GRT) can be significantly 
increased under the fed conditions since the MMC is 
delayed.26 
5.6 Biological factors  
Biological factors such as age, body mass index (BMI), 
gender, posture, and diseased states (diabetes, Chron’s 
disease) influence gastric emptying. In the case of elderly 
persons, gastric emptying is slowed down. Generally females 
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have slower gastric emptying rates than males. GRT can very 
between supine and upright ambulatory states of the 
patients.77 Stress increases gastric emptying rates while 
depression slows it down.36 
5.7 Frequency of feed 
The gastroretentive time can increase by over 400 minutes 
when successive meals are given compared with a single 
meal due to the low frequency of MMC.32 
5.8 Gender 
Mean ambulatory GRT in meals (3.4  0.4 hours) is less 
compared with their age and race-matched female 
counterparts (4.6 1.2 hours), regardless of the weight, 
height and body surface. 
5.9 Posture  
Gastroretentive time can vary between supine and upright 
ambulatory states of the patients 33 
5.10 Volume of liquids 
The resting volume of the stomach is 25 to 50 ml. Volume of 
liquids administered affects the gastric emptying time. When 
volume is large, the emptying is faster. Fluids taken at body 
temperature leave the stomach faster than colder or warmer 
fluids. 
5.11 Effect of size of floating and nonfloating dosage  
Timmermans and Andre34 studied the effect of size of 
floating and nonfloating dosage forms on gastric emptying 
and concluded that the floating units remained buoyant on 
gastric fluids. These are less likely to be expelled from the 
stomach compared with the nonfloating units, which lie in 
the antrum region and are propelled by the peristaltic waves. 
6. FORMULATION OF FLOATING DOSAGE FORM 
Following types of the ingredients can be incorporated in to 
HBS dosage form in addition to drugs.31 
 Hydrocolloids 
 Inert fatty materials 
 Release rate accelerants 
 Release rate retardant 
 Buoyancy increasing agents 
 Miscellaneous 
6.1 Hydrocolloids 
Suitable hydrocolloids are synthetics, anionic or nonionic 
like hydrophilic gums, modified cellulose derivatives. E.g. 
acacia, pectin, agar, alginates, gelatin, casein, bentonite, 
veegum, methyl cellulose, hydroxyl propyl cellulose, 
hydroxyl ethyl cellulose, and sodium carboxy methyl 
cellulose can be used. The hydrocolloids must hydrate in 
acidic medium i.e. gastric fluid having pH 1.2. Although the 
bulk density of the formulation may initially be more than 
one, but when it enters in the gastric fluid system, it should 
be hydrodynamically balanced to have a bulk density of less 
than one to assure buoyancy.  
      6.2 Inert fatty materials 
Edible, pharmaceutically inert fatty material, having a 
specific gravity less than one can be added to the formulation 
to decrease the hydrophilic property of formulation and 
hence increase the buoyancy. Example: Purified grades of 
beeswax, fatty acids, long chain alcohols, glycerides, and 
minaral oils can be used. Such materials may be present from 
about 5 – 75 % by weight. 
6.3 Release rate accelerant 
The release rate of the medicament from the formulation can 
be modified by including excipient like lactose and/or 
mannitol. These may be present from about 5 – 60% by 
weight. 
6.4 Release rate retardant 
Insoluble substances such as dicalcium phosphate, talc, 
magnesium stearate decreased the solubility and hence 
retard the release of medicaments. Such, materials may be 
present about 5 – 60 % by weight. 
      6.5 Buoyancy increasing agents 
Materials like ethyl cellulose, which has bulk density less 
than one, can be used for enhancing the buoyancy of the 
formulation. It may be added up to 80 % by weight. 
      6.6 Miscellaneous 
Pharmaceutically acceptable adjuvant like preservatives, 
stabilizers, and lubricants can be incorporated in the dosage 
forms as per the requirements. They do not adversely affect 
the hydrodynamic balance of the systems.  
7. EVALUATION OF FLOATING SYSTEMS  
Various parameters9 that need to be evaluated in gastro-
retentive formulations include floating duration, dissolution 
profiles, specific gravity, content uniformity, hardness, and 
friability in case of solid dosage forms. In the case of 
multiparticulate drug delivery systems, differential scanning 
calorimetry (DSC), particle size analysis, flow properties, 
surface morphology, and mechanical properties are also 
performed. 
7.1 Floating time 
The test for buoyancy is usually performed in simulated 
gastric and intestinal fluid maintained at 37C. The floating 
time is determined by using USP dissolution apparatus 
containing 900 ml of o.1 N HCl as the testing medium 
maintained at 37C. The time for which the dosage form 
floats is termed as the floating or floatation time.29 
7.2. Swelling index 
The swelling index of tablets was determined n 0.1 N HCl (pH 
1.2) at room temperature. The swollen weight of the tablets 
was determined at predefined time intervals. The swelling 
index was calculated by the following equation: 
Swelling index = Wt – W0 
                     W0 
Where, W0 is the initial weight of tablet, and Wt is the 
weight of the tablet at time t. 
7.3 In vivo study 
In vivo gastric residence time of a floating dosage form is 
determined by X-ray diffraction studies, gamma 
scintigraphy,30 or roentgenography82. In X-ray method the 
formulation is modified to incorporate Barium Sulphate as X-
ray opaque substance. The study is carried out by 
administering the gastroretentive tablets to human 
volunteer. The tablet was administered in the fasting state. 
The X Ray opaque formulation is administered along with 
250 ml of water. The subjects are allowed to remain in sitting 
or upright position. A light meal is given to volunteer 2 hour 
after administration of the tablet to evaluate effect of food of 
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gastroretentive property. The position of tablet is monitored 
by X-Ray screening technique X-Ray photographs taken at 
desired intervals to monitor tablet position in human 
gastrointestinal tract.  
8. ADVANTAGES OF FLOATING DOSAGE FORM 20,31 
 The Principle of HBS may not limited to any particular 
medicament or class of medicament 
 The HBS formulations are not restricted to 
medicaments, which are absorbed from stomach, since 
it has been found that these are equally efficacious with 
medicament, which absorbed from the intestine. 
 Acidic substances like aspirin cause irritation on the 
stomach wall when come in to contact with it. Hence 
HBS formulation may be useful for the administration 
of aspirin and other similar drugs. 
 The HBS are advantageous for drugs absorbed through 
the stomach. e.g. Ferrous salts, antacids. 
 The efficacy of the medicaments administered utilizing 
the sustained release principle of HBS formulation has 
been found to be independent of the site of particular 
medicaments. 
 The HBS are advantageous for drugs meant for local 
action in the stomach. e.g.Antacids. 
 Administration of prolongs release floating dosage 
forms, tablet or capsules, will results in dissolution of 
the drug in the gastric fluid. They dissolve in the gastric 
fluid would be available for absorption in the small 
intestine after emptying of the stomach contents. It is 
therefore expected that a drug will be fully absorbed 
from the floating dosage forms if it remains in the 
solution form even at the alkaline pH of the intestine. 
 When there is vigorous intestinal movement and a 
shorted transit time as might occur in certain type of 
diarrhea, poor absorption is expected. Under such 
circumstances it may be advantageous to keep the drug 
in floating condition in stomach to get a relatively 
better response. 
9. CONCLUSION: 
Floating dosage form offers various future potential as 
evident from several recent publications. The reduced 
fluctuations in the plasma level of drug results from delayed 
gastric emptying. Drugs that have poor bioavailability 
because of their limited absorption to the upper 
gastrointestinal tract can be delivered efficiently thereby 
maximizing their absorption and improving their absolute 
bioavailability. Buoyant delivery system considered as a 
beneficial strategy for the treatment of gastric and duodenal 
cancers. The floating concept can also be utilized in the 
development of various anti-reflux formulations. 
REFERENCES 
1.  Ichikawa, M., Kato, T., Kawahara, M., Watanabe, S., Kayano, M., 
1991. A new multiple-unit oral floating dosage system. II: In vivo 
evaluation of floating and sustained-release characteristics with 
p-aminobenzoic acid and isosorbide dinitrate as model drugs. J. 
Pharm. Sci. 80, 1153–1156. 
2.  Kawashima, Y., Niwa, T., Takeuchi, H., Hi   no, T., Ito, Y., 1991. 
Preparation of multiple unit hollow microspheres 
(microballoons) with acrylicresin containing tranilast and their 
drug release characteristics (in vitro) and floating behavior (in 
vivo). J. Control. Release 16, 279–290. 
3.  Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996. In vivo 
evaluation of a novel gastric retentive formulation based on  ion 
exchange resins. J. Control. Release 42, 105–113.  
4.  Iannuccelli, V., Coppi, G., Sansone, R., Ferolla, G., 1998. Air 
compartment multiple-unit system for prolonged gastric 
residence. Part II. In vivo evaluation. Int. J. Pharm. 174, 55–62. 
5.  Hwang, S.J., Park, H., Park, K., 1998. Gastric retentive drug-
delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 15, 243–284. 
6.  Moës, A.J., 1993. Gastroretentive dosage forms. Crit. Rev. Ther. 
Drug Carrier Syst. 10, 143–195. 
7.  Deshpande, A.A., Rhodes, C.T., Shah, N.H., Malick, A.W., 1996. 
Controlled-release drug delivery systems for prolonged gastric 
residence: an overview. Drug Dev. Ind. Pharm. 22, 531–539.     
8.  Rouge, N., Buri, P., Doelker, E., 1996. Drug absorption sites in the 
gastrointestinal tract and dosage forms for site-specific delivery. 
Int. J. Pharm. 136, 117–139. 
9.  Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: an 
approach to oral controlled drug delivery via gastric retention. J. 
Control. Release 63, 235–259. 
10. Sheth, P.R., Tossounian, J.L., 1979a. Sustained release tablet 
formulations. U.S. Patent 4,140,755. 
11. Sheth, P.R., Tossounian, J.L., 1979b. Novel sustained release 
tablet formulations. U.S. Patent 4,167,558. 
12. Baumgartner, S., Kristl, J., Vrecer, F., Vodopivec, P., Zorko, B., 
2000. Optimisation of floating matrix tablets and evaluation of 
their gastric residence time. Int. J. Pharm. 195, 125–135. 
13. Colombo, P., Provasi, D., Borazzo, M.G., Maggi, L., Catellani, P.L., 
1989. The role of compression force in floating tablet formula 
optimization. Acta Pharm. Technol. 35, 168–170. 
14. Gerogiannis, V.S., Rekkas, D.M., Dallas, P.P., Choulis, N.H., 1993. 
Floating and swelling characteristics of various excipients used 
in controlled release technology. Drug Dev. Ind. Pharm. 19, 
1061–1081. 
15. Rouge, N., Cole, E.T., Doelker, E., Buri, P.,1997. Screening of 
potentially floating excipients for minitablets. STP Pharma Sci. 7, 
386–392. 
16. Baumgartner, S., Smid-Korbar, J.,Vrecer, F., Kristl, J., 1998. 
Physical and technological parameters influencing floating 
properties of matrix tablets based on cellulose ethers. STP 
Pharma Sci. 8, 285–290. 
17. Ingani, H.M., Timmermans, J., Moës, A.J., 1987. Conception and in 
vivo investigation of peroral sustained release floating dosage 
forms with enhanced gastrointestinal transit. Int. J. Pharm. 35, 
157–164. 
18. Yang, L., Fassihi, R., 1996. Zero-order release kinetics from a self- 
correcting floatable asymmetric configuration drug delivery 
system. J. Pharm. Sci. 85, 170–173.  
19. Yang, L., Eshraghi, J., Fassihi, R., 1999. A new intragastric delivery 
system for the treatment of Helicobacter pylori associated 
gastric ulcer: in vitro evaluation. J. Control. Release 57, 215–222. 
20. Timmermans, J., Moës, A.J., 1990. How well do floating dosage 
forms float? Int. J. Pharm. 62, 207–216. 
21. Müller,W., Anders, E., 1989. Floating system for oral therapy.WO 
Patent 89/06956. 
22. Siepmann, J., Peppas, N.A., 2001. Modeling of drug release from 
delivery systems based on hydroxypropyl methylcellulose. Adv. 
Drug Deliv. Rev. 48, 139–157. 
23. Siepmann, J., Streubel, A., Peppas, N.A., 2002. Understanding and 
predicting drug delivery from hydrophilic matrix tablets using 
the ‘‘sequential layer’’ model. Pharm. Res. 19, 306–314. 
24. Velasco, M.V., Ford, J.L., Rowe, P., Rajabi-Siahboomi, A.R., 1999. 
Influence of drug: hydroxypropylmethylcellulose ratio, drug and 
polymer particle size and compression force on the release of 
diclofenac sodium from HPMC tablets.               J. Control. Release 
57, 75–85. 
25. Sung, K.C., Nixon, P.R., Skoug, J.W., Ju, T.R., Gao, P., Topp, E.M., 
Patel, M.V., 1996. Effect of formulation variables on drug and 
polymer release from HPMC-based matrix tablets. Int. J. Pharm. 
142, 53–60. 
26. Colombo, P., Conte, U., Gazzaniga, A., Maggi, L., Sangalli, M.E., 
Peppas, N.A., La Manna, A., 1990. Drug release modulation by 
physical restrictions of matrix swelling. Int. J. Pharm. 63, 43–48. 
27. Conte, U., Maggi, L., Colombo, P., La Manna, A., 1993. Multi-
layered hydrophilic matrices as constant release devices 
(Geomatrix_ Systems). J. Control. Release 26, 39–47. 
28. Desai S. A Novel Floating Controlled Release Drug Delivery 
System Based on a Dried Gel Matrix Network [master’s 
thesis]. [thesis]. Jamaica, NY: St John’s University; 1984.  
29. Vantrappen GR, Peeters TL, Janssens J.  The secretory component 
of interdigestive migratory motor complex in man. Scand J 
Gastroenterol. 1979; 14:663-667.  
Jaimini et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(4):651-656 
 
ISSN: 2250-1177                                                                                   [656]                                                                                     CODEN (USA): JDDTAO 
30. Wilson CG, Washington N. The stomach: its role in oral drug 
delivery. In: Rubinstein MH,  ed. Physiological Pharmacetical: 
Biological Barriers to Drug Absorption. Chichester, UK: Ellis 
Horwood; 1989:47-70.  
31. S Bolton, S Desai, Floating sustained release therapeutic 
compositions, US Patent, 4,814,179,March 21; 1989. 
32. R C Mamajek, E S Moyer, Drug dispensing and method US patent 
4,207,890, June 17; 1980 through C.A.1984 K50391. 
33. L Whitehead, J T Fell J H Collett, Development of a 
Gastroretentive Dosage Form. European Journal of 
Pharmaceutical Sciences; 1996,4 (1): S182. 
34. V Iannuccelli, G Coppi, R Sansone and G Ferolla, Air-
compartment Multiple-unit System for Prolonged Gastric 
Residence, Part II. In vivo Evaluation. International Journal of 
Pharmaceutics; 1998,174 (1–2): 55–62. 
35. N R Jimenez-Castellanos, H Zia and C T Rhodes, Mucoadhesive 
Drug Delivery Systems. Drug Development and Industrial 
Pharmacy; 1993, 19: 143. 
36. R Talukder and R Fissihi, Gastroretentive delivery systems: A 
mini review. Drug Dev. Ind. Pharm.; 2004, 30 (10): 1019-1028.
 
